Same Molecule, Different Names: How to Match Your Tirzepatide Prescription to the Right Product

Tirzepatide is the name that stays the same

If you've looked at a pharmacy label and wondered whether Mounjaro and Zepbound are two different medicines, you're in good company. The Mounjaro vs Zepbound difference comes down mostly to brand names and approved uses, not the molecule inside. Tirzepatide is the international nonproprietary name (INN) assigned by the World Health Organization. It names one active substance. Manufacturers then attach brand names to it, and those brand names are what change on the box.

Here's how it works in plain language. Tirzepatide is a single molecule that activates two hormone receptors: the GIP receptor and the GLP-1 receptor. Many people know GLP-1 from older medicines. Tirzepatide also activates GIP, which is why it's often called a dual agonist. The prescribing information describes this one molecule, whatever name is printed on the carton.

So check the active ingredient line first. The US labels for both products list tirzepatide as the active ingredient. In the EU and UK, the authorised product is Mounjaro, and its product information also names tirzepatide as the active ingredient. If the line reads tirzepatide, you're looking at the same molecule, even when the brand differs.

Why Mounjaro and Zepbound carry different labels

The FDA approved Mounjaro in May 2022 for adults with type 2 diabetes, as an add-on to diet and exercise. Zepbound followed in November 2023 for chronic weight management in adults with obesity, or with overweight plus at least one weight-related condition. Two approvals, two indications, two brand names.

The brand follows the approved use and the company's marketing decision, not a different chemical. One molecule received two approved uses, and each use carries its own name.

Indications can also expand. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The indication list you read last year may look different now, so check the current Zepbound label on DailyMed before you rely on it. Labels get updated.

Reading the label: the fields that actually matter

A carton or pen is crowded with text, but three fields do most of the work when you match a prescription.

• Active ingredient: should read tirzepatide.
• Indication: the section stating what the product is officially approved to treat, such as diabetes or weight management.
• Dosage form and strength: whether it's a pen or vial, the strength per dose, and the dosing schedule.

The NDC, or National Drug Code, is the most precise identifier. It's printed on the carton and often on the pen, and it identifies the exact product and package. It has three segments separated by hyphens: a labeler code, a product code, and a package code. The number of digits in each segment varies by package, so don't expect every box to look identical. The FDA NDC Directory is free and public. Enter the number there to confirm the product name, labeler, and package details. For a step-by-step version of this check, our label-reading checklist on MounjaBlog covers the same fields in order.

What to do when the pharmacy or insurer says the name doesn't match

A mismatch usually has a simple cause. The prescription may name one brand while the pharmacy stocks or bills the other. A new pen design or package can also look unfamiliar enough to trigger a flag.

Ask your prescriber to confirm three things in writing: the active ingredient, the indication, and the dosage form. A short portal message with those details often clears up the confusion. Ask them to confirm the strength too, so the pharmacy has a complete picture.

Insurers often check the diagnosis code on the claim. ICD-10-CM codes classify type 2 diabetes and obesity, and a code that doesn't fit the approved indication can prompt a request for more information. Some plans also require prior authorization, which means your prescriber submits clinical details before the plan agrees to cover the drug. Rules vary by plan, so ask your insurer exactly what documentation it needs.

Questions to bring to your doctor visit

Appointments move quickly, so bring a written list. Start with the indication. Ask which condition the prescription is for and whether it matches why you take the medicine. If you have type 2 diabetes but the prescription says weight management, or the reverse, raise it right away.

Next, ask whether the product name on the prescription is the one you should expect at the pharmacy. Then ask what to do if the dispensed product looks different from your last refill. A new pen design, box color, or name can happen. Confirm it with the pharmacist and check that the active ingredient still reads tirzepatide.

Finally, ask how the doctor records the indication in your chart. That entry often drives insurance decisions, so it helps to know what was written. The question list we keep on MounjaBlog is a useful starting point, and you can adapt it before your next appointment.

Checking outside the US and when the name changes

Brand names change from country to country. Brazil's regulator, Anvisa, publishes the bula, the official leaflet for each approved product. The European Medicines Agency publishes an EPAR for each medicine, and the UK's MHRA publishes product information in its online database. Each document lists the active ingredient, indication, and dosage form, even when the brand on your box differs from the one on a US label.

So compare official documents by their contents, not their brand names. Put the active ingredient, indication, and dosage form side by side. If all three match, you're looking at the same medicine under a different name. If one field differs, call the prescriber or pharmacist before you assume anything. A product name on a website or social media post is not the approved label, so treat it as a clue to verify. If you want to compare topics before checking the official documents, the MounjaBlog homepage has the full index of guides.

FAQ

Are Mounjaro and Zepbound the same medicine?

They share the same active ingredient, tirzepatide, but they are approved under different brand names for different indications. Confirm the indication on your prescription before assuming it fits your situation.

Where do I find the NDC on my medication?

The NDC appears on the carton and often on the pen. You can look up the number in the free FDA NDC Directory to confirm the product name, labeler, and package details.

Does the active ingredient tell me my dose?

No. The active ingredient identifies the molecule, but your dose depends on the strength, dosage form, and schedule your prescriber set. Compare those fields on the label with your prescription.

Why does my insurer ask for a diagnosis code?

Insurers use diagnosis codes, such as ICD-10-CM codes for type 2 diabetes or obesity, to check whether a drug fits an approved indication. Ask your prescriber which code was used and whether the plan needs prior authorization.

Sources

• World Health Organization: International Nonproprietary Names (INN) Programme
• DailyMed: Mounjaro (tirzepatide) prescribing information search
• DailyMed: Zepbound (tirzepatide) prescribing information search
• Drugs@FDA: Mounjaro (NDA 215866)
• Drugs@FDA: Zepbound (NDA 217806)
• FDA National Drug Code (NDC) Directory
• European Medicines Agency: Mounjaro EPAR
• Anvisa: Bulário Eletrônico (product leaflets)
• UK MHRA: Products database (product information)
• CDC/NCHS: International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)